IA
ABCL icon

IFP Advisors’s AbCellera Biologics ABCL Stock Holding History

IFP Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4K Hold
4,132
– – ﹤0.01% 2669
2026
Q1 		$14.4K Buy
4,132
+1,793
+77% +$6.45K ﹤0.01% 2963
2025
Q4 		$8K Buy
+2,339
New +$10.4K ﹤0.01% 3183
2022
Q4 		– Sell
-1,080
Closed -$64K – 4586
2022
Q3 		$64K Buy
+1,080
New +$11.8K ﹤0.01% 2182

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

IFP Advisors's ABCL Position: Q2 2026 in Review

IFP Advisors held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 4,132 shares worth $32.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2669.

IFP Advisors first reported a position in ABCL in Q3 2022 and has held it in 4 quarters since. The position peaked at $64K in Q3 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • IFP Advisors held 4,132 shares of AbCellera Biologics worth $32.4K as of Q2 2026.
  • IFP Advisors left its AbCellera Biologics share count unchanged in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2669 holding.
  • IFP Advisors first reported a position in AbCellera Biologics in Q3 2022 and has held it in 4 quarters since.
  • IFP Advisors's AbCellera Biologics position peaked at $64K in Q3 2022.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.